Loading...

Syndax Pharmaceuticals

DB:1T3
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
1T3
DB
$157M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The last earnings update was 45 days ago. More info.


Add to Portfolio Compare Print
  • Syndax Pharmaceuticals has significant price volatility in the past 3 months.
1T3 Share Price and Events
7 Day Returns
-6.2%
DB:1T3
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-37%
DB:1T3
-10.2%
DE Biotechs
-6%
DE Market
1T3 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Syndax Pharmaceuticals (1T3) -6.2% 28.9% 9.3% -37% -60.1% -
DE Biotechs -2.4% 3.2% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • 1T3 underperformed the Biotechs industry which returned -10.2% over the past year.
  • 1T3 underperformed the Market in Germany which returned -6% over the past year.
Price Volatility
1T3
Industry
5yr Volatility vs Market
Related Companies

1T3 Value

 Is Syndax Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Syndax Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is €5.441.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Syndax Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Syndax Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:1T3 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-2.92
NasdaqGS:SNDX Share Price ** NasdaqGS (2019-04-18) in USD $6.29
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Syndax Pharmaceuticals.

DB:1T3 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:SNDX Share Price ÷ EPS (both in USD)

= 6.29 ÷ -2.92

-2.16x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Syndax Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Syndax Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Syndax Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:1T3 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.16x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts
24.7%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Syndax Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Syndax Pharmaceuticals's assets?
Raw Data
DB:1T3 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $2.14
NasdaqGS:SNDX Share Price * NasdaqGS (2019-04-18) in USD $6.29
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:1T3 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:SNDX Share Price ÷ Book Value per Share (both in USD)

= 6.29 ÷ 2.14

2.94x

* Primary Listing of Syndax Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Syndax Pharmaceuticals is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Syndax Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Syndax Pharmaceuticals has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

1T3 Future Performance

 How is Syndax Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
24.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Syndax Pharmaceuticals expected to grow at an attractive rate?
  • Syndax Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Syndax Pharmaceuticals's earnings growth is expected to exceed the Germany market average.
  • Syndax Pharmaceuticals's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:1T3 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:1T3 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts 24.7%
DB:1T3 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts 58%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:1T3 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:1T3 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 162 22 3
2022-12-31 83 -40 3
2021-12-31 36 -19 -69 4
2020-12-31 12 -77 -72 7
2019-12-31 1 -54 -60 6
DB:1T3 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 2 -69 -74
2018-09-30 2 -66 -74
2018-06-30 2 -58 -72
2018-03-31 2 -55 -67
2017-12-31 2 -47 -61
2017-09-30 1 -45 -53
2017-06-30 1 -46 -52
2017-03-31 1 -41 -47
2016-12-31 1 -35 -47
2016-09-30 1 -29 -45
2016-06-30 1 -23 -87
2016-03-31 1 -20 -105

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Syndax Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Syndax Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:1T3 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below

All data from Syndax Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1T3 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.65 2.42 -0.65 3.00
2022-12-31 -0.78 -0.20 -1.28 3.00
2021-12-31 -1.93 -1.53 -2.20 3.00
2020-12-31 -2.01 -1.54 -2.46 5.00
2019-12-31 -2.05 -1.73 -2.44 5.00
DB:1T3 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -2.92
2018-09-30 -3.01
2018-06-30 -3.02
2018-03-31 -2.98
2017-12-31 -2.90
2017-09-30 -2.69
2017-06-30 -2.84
2017-03-31 -2.61
2016-12-31 -3.22
2016-09-30 -4.47
2016-06-30 -15.44
2016-03-31 -88.05

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Syndax Pharmaceuticals will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Syndax Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Syndax Pharmaceuticals has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

1T3 Past Performance

  How has Syndax Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Syndax Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Syndax Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Syndax Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Syndax Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Syndax Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Syndax Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1T3 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 1.52 -73.96 17.29 60.11
2018-09-30 2.33 -74.23 17.48 60.88
2018-06-30 2.26 -71.98 16.92 58.98
2018-03-31 2.18 -67.23 16.72 53.99
2017-12-31 2.11 -60.80 15.86 48.20
2017-09-30 1.22 -52.51 14.75 39.98
2017-06-30 1.22 -52.39 14.46 40.06
2017-03-31 1.22 -47.11 12.98 36.33
2016-12-31 1.22 -47.07 13.32 31.67
2016-09-30 1.22 -45.03 11.45 25.78
2016-06-30 1.22 -86.72 11.37 16.47
2016-03-31 0.93 -104.70 11.85 12.61
2015-12-31 0.63 -103.85 11.59 9.55
2015-09-30 0.32 -100.26 11.03 8.42
2015-06-30 0.02 -53.02 13.86 7.76
2015-03-31 -32.80 12.02 9.76
2014-12-31 -26.36 11.16 10.18
2014-09-30 -31.14 11.14 9.78
2014-06-30 -72.27 6.56 8.32
2014-03-31 -66.64 6.47 4.77
2013-12-31 -60.45 5.36 3.21
2013-09-30 -53.18 3.93 2.78
2012-12-31 -9.97 3.49 5.24

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Syndax Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Syndax Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Syndax Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Syndax Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Syndax Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

1T3 Health

 How is Syndax Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Syndax Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Syndax Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Syndax Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Syndax Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Syndax Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Syndax Pharmaceuticals Company Filings, last reported 3 months ago.

DB:1T3 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 53.05 0.00 81.57
2018-09-30 64.27 0.00 91.52
2018-06-30 70.35 0.00 99.79
2018-03-31 86.95 0.00 113.99
2017-12-31 104.32 0.00 131.26
2017-09-30 96.71 0.00 121.49
2017-06-30 109.34 0.00 131.96
2017-03-31 72.62 0.00 95.20
2016-12-31 84.14 0.00 106.96
2016-09-30 93.83 0.00 116.00
2016-06-30 106.24 0.00 125.89
2016-03-31 113.85 0.00 134.32
2015-12-31 66.70 0.00 87.29
2015-09-30 70.76 8.18 100.46
2015-06-30
2015-03-31 -5.72 13.88 12.21
2014-12-31 -5.72 13.88 12.21
2014-09-30 -2.58 9.82 11.69
2014-06-30 4.31 0.00 5.01
2014-03-31 8.43 0.00 9.50
2013-12-31 11.85 0.00 14.26
2013-09-30 -4.48 1.49 5.07
2012-12-31 -27.47 21.34 0.63
  • Syndax Pharmaceuticals has no debt.
  • Syndax Pharmaceuticals had no debt 5 years ago.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Syndax Pharmaceuticals has sufficient cash runway for 1.2 years based on current free cash flow.
  • Syndax Pharmaceuticals has sufficient cash runway for 1.2 years if free cash flow continues to grow at historical rates of 46.3% each year.
X
Financial health checks
We assess Syndax Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Syndax Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

1T3 Dividends

 What is Syndax Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Syndax Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought €2,000 of Syndax Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Syndax Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Syndax Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:1T3 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:1T3 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Syndax Pharmaceuticals has not reported any payouts.
  • Unable to verify if Syndax Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Syndax Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Syndax Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Syndax Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Syndax Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Syndax Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Syndax Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

1T3 Management

 What is the CEO of Syndax Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Briggs Morrison
COMPENSATION $1,677,097
AGE 58
TENURE AS CEO 3.8 years
CEO Bio

Dr. Briggs W. Morrison, M.D. serves as the Executive Partner MPM Capital. He joined MPM in 2015. He is the Chairman of Scientific Advisory Board at Cerenis Therapeutics Holding SA since May 2018. Dr. Morrison has been the Chief Executive Officer of Syndax Pharmaceuticals, Inc. since June 22, 2015. Dr. Morrison has been Managing Director at MPM Capital since June 22, 2015. Dr. Morrison joined MPM Capital in 2015. He served as an Executive Vice President for Global Medicines Development and Chief Medical Officer at AstraZeneca PLC from January 2012 to June 2015. In his role as Head of Global Medicines Development, Dr. Morrison oversaw all clinical development functions and late stage clinical development projects at AstraZeneca. During his tenure, AstraZeneca rebuilt its Phase 3 pipeline with a focus on Oncology, Respiratory and Cardiovascular/Metabolic molecules. He served as a Senior Vice President/Head of Clinical Development of Pfizer Inc. since October 4, 2007 until January 2012. He held a number of positions at Pfizer Inc. from 2007 to 2012 that culminated in his appointment as Head, Medical Affairs, Safety and Regulatory Affairs for Pfizerâ s human health business. Dr. Morrison serves as a Director of Arvinas, Inc since June 2018. Dr. Morrison was responsible for the clinical development of all compounds in Pfizer's portfolio, he played a key role in implementing strategies to advance key compounds to approval. He oversaw Phase I – III development for all therapeutic areas as well as clinical operations. He later oversaw Development, Medical Affairs, Safety and Regulatory Affairs for all Pfizer human health businesses and served as Head of the Medicines Development Group for the Primary Care Business Unit, overseeing Development, Medical Affairs, Market Access and early commercial development. Previously, Dr. Morrison served as Senior Vice President of Research Planning and Integration of Merck & Co., Inc. and its head of Global Clinical Development Operations. He served in senior research and clinical data management positions as Executive Director and Vice President for all Clinical Data Management Operations, where he was responsible for all clinical data management across the entire research portfolio. He worked at Merck Research Laboratories from 1995 to 2007, ascending to the role of Vice President, Clinical Sciences, Oncology, responsible for clinical development of all novel anti-cancer drugs. He also worked as the Head of the Oncology Development group at Merck & Co., Inc., overseeing the development and approval of vorinostat (Zolinza) for the treatment of cutaneous T-cell lymphoma. From 2004 to 2006, he was on a special assignment to review and enhance the effectiveness of Merck's research operations and led the restructuring of the research division and its processes. He served as Chairman of the Board of Transcelerate BioPharma from 2014 to 2015. He serves as Board of Director of ACRES (Alliance for Clinical Research Excellence and Safety), ImunoMet Therapeutics, Inc. and Oncorus, Inc. He has been a Director of RIFT Biotherapeutics Inc. since March 2017 and NextCure, Inc. since April 2019. He has been a Member of Advisory Board of Tyme Technologies, Inc. since September 14, 2017. Dr. Morrison has been a Director of Syndax Pharmaceuticals, Inc. since July 2015 and ImmunoMet Therapeutics, Inc. since November 28, 2017. He is an instructor in medicine at the Harvard Medical School. He completed his internship and residency in Internal Medicine at the Massachusetts General Hospital, a fellowship in Medical Oncology at the Dana-Farber Cancer Institute and a post-doctoral research fellowship in Genetics at Harvard Medical School. Dr. Morrison received a B.S. in Biology from Georgetown University and holds an M.D. from the University of Connecticut School of Medicine.

CEO Compensation
  • Briggs's compensation has increased whilst company is loss making.
  • Briggs's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Syndax Pharmaceuticals management team in years:

3.8
Average Tenure
59.5
Average Age
  • The tenure for the Syndax Pharmaceuticals management team is about average.
Management Team

Briggs Morrison

TITLE
CEO & Director
COMPENSATION
$2M
AGE
58
TENURE
3.8 yrs

Michael Metzger

TITLE
President & COO
COMPENSATION
$1M
AGE
47
TENURE
3.9 yrs

Rick Shea

TITLE
CFO & Treasurer
COMPENSATION
$13K
AGE
66
TENURE
2.2 yrs

Michael Meyers

TITLE
Chief Medical Officer & Senior VP
COMPENSATION
$934K
AGE
67
TENURE
3.7 yrs

Peter Ordentlich

TITLE
Co-Founder & Chief Scientific Officer
AGE
49
TENURE
13.5 yrs

Rich Heyman

TITLE
Co-Founder
AGE
61

Ronald Evans

TITLE
Co-Founder

Michael Downes

TITLE
Co-Founder

Luke Albrecht

TITLE
General Counsel & Corporate Secretary

Ed Sausville

TITLE
Board of Directors Tenure

Average tenure and age of the Syndax Pharmaceuticals board of directors in years:

2.8
Average Tenure
57
Average Age
  • The average tenure for the Syndax Pharmaceuticals board of directors is less than 3 years, this suggests a new board.
Board of Directors

Dennis Podlesak

TITLE
Chairman
COMPENSATION
$213K
AGE
60
TENURE
10.3 yrs

Briggs Morrison

TITLE
CEO & Director
COMPENSATION
$2M
AGE
58
TENURE
3.8 yrs

Ronald Evans

TITLE
Co-Founder
TENURE
2.8 yrs

Pierre Legault

TITLE
Director
COMPENSATION
$281K
AGE
57
TENURE
2.3 yrs

Keith Katkin

TITLE
Director
COMPENSATION
$376K
AGE
47
TENURE
2.1 yrs

George Sledge

TITLE
Member of Scientific Advisory Board
COMPENSATION
$23K
AGE
66
TENURE
2 yrs

Jay Lichter

TITLE
Observer
AGE
56

Fabrice Egros

TITLE
Director
COMPENSATION
$174K
AGE
55
TENURE
5.6 yrs

Julie Brahmer

TITLE
Member of Scientific Advisory Board
TENURE
3.3 yrs

Joseph Eder

TITLE
Member of Scientific Advisory Board
TENURE
2.8 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Syndax Pharmaceuticals insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
25. Mar 19 Buy Michael Meyers Individual 21. Mar 19 21. Mar 19 1,112 €4.35 €4,826
07. Nov 18 Buy Michael Meyers Individual 30. Oct 18 30. Oct 18 200 €4.22 €843
X
Management checks
We assess Syndax Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Syndax Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

1T3 News

Simply Wall St News

1T3 Company Info

Description

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company’s lead product candidates include entinostat, which is in Phase III clinical trials for the treatment of advanced hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer; and SNDX-5613 inhibitor that targets the binding interaction of Menin with mixed lineage leukemia-rearranged and acute myeloid leukemia with a mutated nucleophosmin 1. It also develops entinostat with Keytruda (pembrolizumab) in a Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and melanoma or microsatellite stable colorectal carcinoma; with Tecentriq (atezolizumab) in a Phase Ib/II clinical trials to treat patients with triple-negative breast cancer, and HR+ and HER2- metastatic breast cancer; and with Bavencio (avelumab) in a Phase Ib/II clinical trials for the treatment of ovarian cancer. In addition, the company develops SNDX-6352, a monoclonal antibody that blocks the colony stimulating factor 1 that is in Phase I dose escalation trial in patients with chronic graft versus host disease; and as a monotherapy and in combination with Imfinzi (durvalumab), which is in Phase I/Ib dose trials for the treatment of solid tumors. Syndax Pharmaceuticals, Inc. has clinical collaborations with MSD International GmbH; Genentech, Inc.; Merck KGaA and Pfizer; and AstraZeneca plc. It also has collaborative research and development agreement with National Cancer Institute; clinical trial agreement with Eastern Cooperative Oncology Group; and license agreement with Kyowa Hakko Kirin Co., Ltd. The company was founded in 2005 and is headquartered in Waltham, Massachusetts.

Details
Name: Syndax Pharmaceuticals, Inc.
1T3
Exchange: DB
Founded: 2005
$139,830,838
25,000,740
Website: http://www.syndax.com
Address: Syndax Pharmaceuticals, Inc.
35 Gatehouse Drive,
Building D,
Waltham,
Massachusetts, 02451,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS SNDX Common Stock Nasdaq Global Select US USD 03. Mar 2016
DB 1T3 Common Stock Deutsche Boerse AG DE EUR 03. Mar 2016
Number of employees
Current staff
Staff numbers
38
Syndax Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 21:36
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/12
Last earnings filing: 2019/03/07
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.